

Table 1. Demographic, clinical and immunological characteristics of the nevirapine sensitive and tolerant patient groups, according to race.

Factors at NVP initiation	Caucasian			Asian		
	Nevirapine Sensitive (n=13)	Nevirapine Tolerant (n=239)	P*	Nevirapine Sensitive (n=6)	Nevirapine Tolerant (n=23)	P*
Demographic						
Male	84.6%	92.5%	0.3	33.3%	56.5%	0.4
Age (median [IQR] years)	44.1 [39.0-48.6]	40.9 [35.6-49.8]	0.5	28 [22.2-36.4]	35.4 [30.3-40.3]	0.2
Clinical factors						
HCV co-infected	7.7%	10.9%	>0.9	16.7%	13%	>0.9
Rx experienced	76.9%	66.9%	0.6	33.3%	60.9%	0.4
Viral load≤400 cps/mL	54.5%	44.2%	0.5	50%	52.4%	>0.9
Immunological status (median [IQR])						
CD4%	32 [23-37]	21 [15-30]	0.1	17 [10-22]	17 [12-23]	0.7
CD4+ T cells	468 [379-778]	420 [264-627]	0.3	351 [282-566]	324 [234-422]	0.5
CD8%	49 [43-54]	52 [42-60]	0.7	42 [38-52]	48 [42-61]	0.4
CD8+ T cells	882 [765-1502]	993 [681-1442]	>0.9	1159 [950-2236]	806 [580-1200]	0.2

* P-values for comparison of nevirapine sensitive and tolerant groups, obtained from either a Wilcoxon test (continuous variables) or a Fisher exact test (dichotomous variables).

Table 2. HLA allelic associations with nevirapine hypersensitivity amongst 252 Caucasians (13 sensitive; 239 tolerant) and 29 Asians (6 sensitive).

HLA allele	Nevirapine hypersensitivity reaction (NVP HSR) vs NVP tolerant						
	Frequency		All NVP HSR	HSR with hepatic symptoms	HSR with rash	HSR with eosinophilia	Multisystemic HSR
	Caucasian	Asian	MH P-value* (logistic)	MH P-value* (logistic)	MH P-value* (logistic)	MH P-value* (logistic)	MH P-value* (logistic)
DRB1*01:01							
NVP HSR	46.2%	0.0%	0.03	0.02	0.4	0.9	0.1
tolerant	14.1% [#]	9.1% [^]	(OR=3.7, P=0.04)	(OR=4.2, P=0.02)	(OR=2.2, P=0.4)	(OR=2.2, P=0.4)	(OR=3.1, P=0.1)
B*35:01							
NVP HSR	30.8%	33.3%	0.005	0.08	0.001	0.9	0.2
tolerant	10.5%	0.0% [†]	(OR=5.1, P=0.01)	(OR=3.1, P=0.1)	(OR=7.9, P=0.006)	(OR=1.4, P=0.8)	(OR=2.7, P=0.3)
Cw*04							
NVP HSR	30.8%	66.7%	0.08	0.3	0.01	0.8	0.4
tolerant	17.1% [‡]	27.3% [†]	(OR=2.2, P=0.2)	(OR=1.5, P=0.5)	(OR=4.1, P=0.04)	(OR=0.6, P=0.6)	(OR=1.4, P=0.6)
Cw*08							
NVP HSR	15.4%	33.3%	0.1	0.07	0.07	0.04	0.02
tolerant	8.8% [‡]	0.0% [†]	(OR=3.0, P=0.1)	(OR=3.6, P=0.06)	(OR=4.9, P=0.05)	(OR=4.2, P=0.08)	(OR=4.9, P=0.03)

* P-value obtained from race-stratified Mantel-Haenszel test; logistic models adjusted for race, therapy backbone and CD4+ T cells at nevirapine initiation. [#]Data available for 234/239; [‡]Data available for 217/239; [^]Data available for 22/23; [†]Data available for 22/23.